118 related articles for article (PubMed ID: 30738963)
21. New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Mascarenhas CC; Cunha AF; Miranda EC; Zulli R; Silveira RA; Costa FF; Pagnano KB; De Souza CA
Leuk Lymphoma; 2009 Jul; 50(7):1148-54. PubMed ID: 19557636
[TBL] [Abstract][Full Text] [Related]
22. Association of Vascular Endothelial Growth Factor A (VEGFA) and its Receptor (VEGFR2) Gene Polymorphisms with Risk of Chronic Myeloid Leukemia and Influence on Clinical Outcome.
Lakkireddy S; Aula S; Kapley A; Swamy AV; Digumarti RR; Kutala VK; Jamil K
Mol Diagn Ther; 2016 Feb; 20(1):33-44. PubMed ID: 26476544
[TBL] [Abstract][Full Text] [Related]
23. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
24. The Association of rs2114358 in the miR-1206 Polymorphism to Chronic Myeloid Leukemia.
Hassan FM
Microrna; 2019; 8(3):248-252. PubMed ID: 30605069
[TBL] [Abstract][Full Text] [Related]
25. Clonal distribution of BCR-ABL1 mutations and splice isoforms by single-molecule long-read RNA sequencing.
Cavelier L; Ameur A; Häggqvist S; Höijer I; Cahill N; Olsson-Strömberg U; Hermanson M
BMC Cancer; 2015 Feb; 15():45. PubMed ID: 25880391
[TBL] [Abstract][Full Text] [Related]
26. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
27. Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene.
Nishioka C; Ikezoe T; Yang J; Yokoyama A
Leukemia; 2010 Sep; 24(9):1631-40. PubMed ID: 20596030
[TBL] [Abstract][Full Text] [Related]
28. [Association of CD38 gene polymorphism with pathogenesis of chronic myeloid leukemia].
Li J; Zhu JF; Zhang W; Ma HZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):284-7. PubMed ID: 21518472
[TBL] [Abstract][Full Text] [Related]
29. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
30. [Regulation of wild type PTEN gene on Survivin, Xiap and Smac in chronic leukemia cells].
Cheng ZY; Wan JS; Wang YL; Liang LQ; Liang WT; Mu J; Lu X; Pan L
Zhonghua Yi Xue Za Zhi; 2011 Nov; 91(40):2868-72. PubMed ID: 22333553
[TBL] [Abstract][Full Text] [Related]
31. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.
Mullighan CG; Miller CB; Radtke I; Phillips LA; Dalton J; Ma J; White D; Hughes TP; Le Beau MM; Pui CH; Relling MV; Shurtleff SA; Downing JR
Nature; 2008 May; 453(7191):110-4. PubMed ID: 18408710
[TBL] [Abstract][Full Text] [Related]
32. [Molecular pathogenesis of chronic myeloid leukemia].
Sasaki K; Mitani K
Nihon Rinsho; 2009 Oct; 67(10):1894-9. PubMed ID: 19860186
[TBL] [Abstract][Full Text] [Related]
33. Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia.
Gupta M; Milani L; Hermansson M; Simonsson B; Markevärn B; Syvänen AC; Barbany G
Biochem Biophys Res Commun; 2008 Feb; 366(3):848-51. PubMed ID: 18082628
[TBL] [Abstract][Full Text] [Related]
34. The genetic polymorphism and expression profiles of NLRP3 inflammasome in patients with chronic myeloid leukemia.
Zhang A; Yu J; Yan S; Zhao X; Chen C; Zhou Y; Zhao X; Hua M; Wang R; Zhang C; Zhong C; He N; Ji C; Ma D
Hum Immunol; 2018 Jan; 79(1):57-62. PubMed ID: 29097263
[TBL] [Abstract][Full Text] [Related]
35. Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
Luatti S; Baldazzi C; Marzocchi G; Ameli G; Bochicchio MT; Soverini S; Castagnetti F; Tiribelli M; Gugliotta G; Martinelli G; Baccarani M; Cavo M; Rosti G; Testoni N
Oncotarget; 2017 May; 8(18):29906-29913. PubMed ID: 28404889
[TBL] [Abstract][Full Text] [Related]
36. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia.
Loncarevic IF; Römer J; Starke H; Heller A; Bleck C; Ziegler M; Fiedler W; Liehr T; Clement JH; Claussen U
Genes Chromosomes Cancer; 2002 Jun; 34(2):193-200. PubMed ID: 11979553
[TBL] [Abstract][Full Text] [Related]
37. Expression, prognostic significance and mutational analysis of protein tyrosine phosphatase SHP-1 in chronic myeloid leukemia.
Papadopoulou V; Kontandreopoulou E; Panayiotidis P; Roumelioti M; Angelopoulou M; Kyriazopoulou L; Diamantopoulos PT; Vaiopoulos G; Variami E; Kotsianidis I; Athina Viniou N
Leuk Lymphoma; 2016 May; 57(5):1182-8. PubMed ID: 26373709
[TBL] [Abstract][Full Text] [Related]
38. Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India.
Annamaneni S; Gorre M; Kagita S; Addepalli K; Digumarti RR; Satti V; Battini MR
Hematology; 2013 May; 18(3):163-8. PubMed ID: 23320983
[TBL] [Abstract][Full Text] [Related]
39. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
40. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
